

Allergic Rhinitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/A7F774850DB7EN.html>

Date: July 2022

Pages: 180

Price: US\$ 2,000.00 (Single User License)

ID: A7F774850DB7EN

Abstracts

Allergic Rhinitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Rhinitis - Drugs In Development, 2022, provides an overview of the Allergic Rhinitis (Respiratory) pipeline landscape.

Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy runny nose, sneezing, swollen eyelids, itchy mouth, throat, ears.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Rhinitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 13, 17, 14, 4, 12 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 5 and 4 molecules, respectively.

Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis (Respiratory).

The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Allergic Rhinitis (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Allergic Rhinitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis (Respiratory)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Allergic Rhinitis - Overview

Allergic Rhinitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Allergic Rhinitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Allergic Rhinitis - Companies Involved in Therapeutics Development

Allergic Rhinitis - Drug Profiles

Allergic Rhinitis - Dormant Projects

Allergic Rhinitis - Discontinued Products

Allergic Rhinitis - Product Development Milestones

Featured News & Press Releases

Jul 22, 2022: Revelation Biosciences announces topline data for phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis

Jul 14, 2022: Revelation Biosciences inc. completes database lock for its phase 1b clear clinical study of REVTx-99b for the treatment of allergic rhinitis

Jun 13, 2022: Revelation Biosciences announces completion of dosing for a phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis

May 23, 2022: Revelation Biosciences announces Safety Monitoring Committee recommendation for continuing evaluation of REVTx-99b for the treatment of allergic rhinitis

Apr 07, 2022: Grand Pharmaceutical Group : Phase III clinical trial of global innovative drug Ryaltris compound nasal spray successfully completed the first patient enrollment in China

Mar 16, 2022: Wowu Bio: first subject enrolled in the clinical trial after the launch of Artemisia annua pollen allergen sublingual drops

Mar 01, 2022: Miravo Healthcare announces the Canadian commercial launch of Blexten for patients 4 years of age and older

Jan 24, 2022: Zhejiang Wolwo Bio-Pharma announcement on obtaining the summary

report of the phase III clinical trial of Artemisia annua Pollen Allergen Sublingual drops for children with rhinitis

Jan 18, 2022: Revelation Biosciences announces first patient enrolled and dosed in phase 1b clinical study of REVTx-99 for the treatment of allergic rhinitis

Jan 14, 2022: Glenmark Specialty S.A. (Switzerland) receives NDA approval by the United States Food and Drug Administration (FDA) for Ryaltris nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and pediatric patients 12 years of age and older

Nov 15, 2021: Revelation Biosciences announces initiation of a phase 1b clinical study of REVTx-99 for the experimental treatment of allergic rhinitis and chronic nasal congestion

Oct 20, 2021: The global innovative drug Ryaltris compound nasal spray has been granted phase three clinical trial approval

Sep 30, 2021: Glenmark receives marketing approval for Ryaltris, an innovative combination nasal spray, in 13 countries across the EU and UK

Jun 23, 2021: Nasus Pharma announces positive results from a pilot clinical study of FMXIN002 intranasal powder epinephrine spray in patients with Seasonal Allergic Rhinitis

Jun 08, 2021: Medicilon assists Palaatu to obtain clinical approval for Class 1 new drug PA9159 for rhinitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Allergic Rhinitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Allergic Rhinitis - Pipeline by Advagene Biopharma Co Ltd, 2022
Allergic Rhinitis - Pipeline by ALK-Abello AS, 2022
Allergic Rhinitis - Pipeline by Alkem Laboratories Ltd, 2022
Allergic Rhinitis - Pipeline by Allovate LLC, 2022
Allergic Rhinitis - Pipeline by AOBiome LLC, 2022
Allergic Rhinitis - Pipeline by ASIT Biotech SA, 2022
Allergic Rhinitis - Pipeline by AtoGen Co Ltd, 2022
Allergic Rhinitis - Pipeline by Bai Shuo Beijing Pharmaceutical Technology Co Ltd, 2022
Allergic Rhinitis - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics Inc, 2022
Allergic Rhinitis - Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Allergic Rhinitis - Pipeline by Dobecure SL, 2022
Allergic Rhinitis - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
Allergic Rhinitis - Pipeline by Emergo Therapeutics Inc, 2022
Allergic Rhinitis - Pipeline by EmphyCorp Inc, 2022
Allergic Rhinitis - Pipeline by Eurofarma Laboratorios SA, 2022
Allergic Rhinitis - Pipeline by Faes Farma SA, 2022
Allergic Rhinitis - Pipeline by FunPep Co Ltd, 2022
Allergic Rhinitis - Pipeline by Genu Pharma Co Ltd, 2022
Allergic Rhinitis - Pipeline by GL Pharm Tech Corp, 2022
Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd, 2022
Allergic Rhinitis - Pipeline by HAL Allergy BV, 2022
Allergic Rhinitis - Pipeline by Inimmune Corp, 2022
Allergic Rhinitis - Pipeline by Inmunotek SL, 2022
Allergic Rhinitis - Pipeline by Liminal BioSciences Inc, 2022
Allergic Rhinitis - Pipeline by Link Health Group, 2022

Allergic Rhinitis - Pipeline by Marinomed Biotech AG, 2022
Allergic Rhinitis - Pipeline by MD Healthcare Inc, 2022
Allergic Rhinitis - Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Allergic Rhinitis - Pipeline by Nasus Pharma Ltd, 2022
Allergic Rhinitis - Pipeline by Navipharm Co Ltd, 2022
Allergic Rhinitis - Pipeline by NeuCen BioMed Co Ltd, 2022
Allergic Rhinitis - Pipeline by Oneness Biotech Co Ltd, 2022
Allergic Rhinitis - Pipeline by Palo Alto pharmaceuticals Inc, 2022
Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Ltd, 2022
Allergic Rhinitis - Pipeline by PharmaKing Co Ltd, 2022
Allergic Rhinitis - Pipeline by Raphas Co Ltd, 2022
Allergic Rhinitis - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Allergic Rhinitis - Pipeline by Revelation Biosciences Inc, 2022
Allergic Rhinitis - Pipeline by Revolo Biotherapeutics Ltd, 2022
Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, 2022
Allergic Rhinitis - Pipeline by Sama Pharm Co Ltd, 2022
Allergic Rhinitis - Pipeline by Sedor Pharmaceuticals LLC, 2022
Allergic Rhinitis - Pipeline by Shouyao Holding Co Ltd, 2022
Allergic Rhinitis - Pipeline by Siolta Therapeutics Inc, 2022
Allergic Rhinitis - Pipeline by Stallergenes Greer Ltd, 2022
Allergic Rhinitis - Pipeline by Synokem Pharmaceuticals Ltd, 2022
Allergic Rhinitis - Pipeline by The Geneva Biotech Center SA, 2022
Allergic Rhinitis - Pipeline by United Biomedical Inc, 2022
Allergic Rhinitis - Pipeline by Vactech Oy, 2022
Allergic Rhinitis - Pipeline by Wuhan Yicheng Biotechnology Co Ltd, 2022
Allergic Rhinitis - Pipeline by Yuyu Pharma Inc, 2022
Allergic Rhinitis - Pipeline by Zhejiang Wolwo Bio-Pharmaceutical Co Ltd, 2022
Allergic Rhinitis - Pipeline by Zydus Lifesciences Ltd, 2022
Allergic Rhinitis - Dormant Projects, 2022
Allergic Rhinitis - Discontinued Products, 2022
Allergic Rhinitis - Discontinued Products, 2022 (Contd..1)

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Allergic Rhinitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Allergic Rhinitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/A7F774850DB7EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A7F774850DB7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

